Literature DB >> 18649061

A significant interaction between moxifloxacin and warfarin in a patient with a mitral bioprosthetic valve.

Fatih Yildiz1, Behice Kurtaran, Murat Cayli, Aslihan Candevir, Zehra Sümbül.   

Abstract

Moxifloxacin is an advanced-generation fluoroquinolone with a broad spectrum of antimicrobial activity that is not metabolized by cytochrome P450 system. Therefore, the drug interaction of moxifloxacin is rarely seen. It has been reported that moxifloxacin is safe and well tolerable. We aimed to report a drug interaction between moxifloxacin and warfarin in a 74-year-old patient with a prosthetic mitral valve.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18649061     DOI： 10.1007/s00380-008-1050-0

Source DB:  PubMed          Journal:  Heart Vessels        ISSN： 0910-8327            Impact factor:   2.037


  16 in total

1.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

Authors:  Jack Hirsh; Valentin Fuster; Jack Ansell; Jonathan L Halperin
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

2.  Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.

Authors:  Alec Vahanian; Helmut Baumgartner; Jeroen Bax; Eric Butchart; Robert Dion; Gerasimos Filippatos; Frank Flachskampf; Roger Hall; Bernard Iung; Jaroslaw Kasprzak; Patrick Nataf; Pilar Tornos; Lucia Torracca; Arnold Wenink
Journal:  Eur Heart J       Date:  2007-01-26       Impact factor: 29.983

Review 3.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J E Dalen; D R Anderson; L Poller; H Bussey; J Ansell; D Deykin; J T Brandt
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

4.  Profile of moxifloxacin drug interactions.

Authors:  H Stass; D Kubitza
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

5.  Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction.

Authors:  Lindsay M Arnold; Lindsay R Nissen; Tien M H Ng
Journal:  Pharmacotherapy       Date:  2005-06       Impact factor: 4.705

6.  Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis.

Authors:  A S Gallus; R I Baker; B H Chong; P A Ockelford; A M Street
Journal:  Med J Aust       Date:  2000-06-19       Impact factor: 7.738

7.  The interaction of moxifloxacin and warfarin in three elderly patients.

Authors:  Kieran Anthony O'Connor; Denis O'Mahony
Journal:  Eur J Intern Med       Date:  2003-07       Impact factor: 4.487

8.  Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.

Authors:  James R Gavin; Rolf Kubin; Shurjeel Choudhri; Dagmar Kubitza; Hebert Himmel; Rainer Gross; Jutta M Meyer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  INFLUENCE OF FEVER UPON THE ACTION OF 3,3'-METHYLENE-BIS-(4-HYDROXYCOUMARIN) (DICUMAROL).

Authors:  R K Richards
Journal:  Science       Date:  1943-04-02       Impact factor: 47.728

Review 10.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577
View more
  3 in total

1.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Authors:  Nihat Ozer; Nese Cam; Burak Tangurek; Songul Ozer; Huseyin Uyarel; Dilaver Oz; Mehmet Rasit Guney; Figen Ciloglu
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

2.  Moxifloxacin-warfarin interaction.

Authors:  Yan Ji; Youssef Hokayem
Journal:  J Community Hosp Intern Med Perspect       Date:  2012-01-26

3.  Effect of Quinolones Versus Cefixime on International Normalized Ratio Levels After Valve Replacement Surgery with Warfarin Therapy.

Authors:  Anam Liaqat; Arif-Ullah Khan; Muhammad Asad; And Hafsa Khalil
Journal:  Medicina (Kaunas)       Date:  2019-09-26       Impact factor: 2.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.